Health
1 read
FDA Issues Warning to Novo Nordisk for Reporting Failures on GLP-1 Drugs

Want the full story?
Read the complete article at KTSM
AI Summary
The FDA has formally warned Novo Nordisk for not adequately reporting serious adverse effects, including fatalities, associated with its GLP-1 medications, such as Ozempic and Wegovy. This warning raises concerns about patient safety and the transparency of drug side effects. The agency's action underscores the importance of monitoring and reporting adverse events in pharmaceutical treatments. Patients using these medications should be aware of potential risks and consult healthcare providers for guidance.
health fda pharmaceuticals ozempic wegovy
People & Organizations
Novo NordiskU.S. Food and Drug Administration